NeoEribulin: A Phase II, non-randomized, open-label, single-arm, multicenter, exploratory pharmacogenomic study of single-agent eribulin as neoadjuvant treatment for operable Stage I-II HER2 non-overexpressing breast cancer

Aleix Prat1,3, Antonio Llombart2,3, Lorena de la Peña3, Serena Di Cosimo3,4, Vanesa Ortega1, Isabel Rubio1,3, Eva Muñoz1, Nadia Harbeck4, and Javier Cortés1,3

1Vall d’Hebron University Hospital, Barcelona, Spain; 2Hospital Arnaud de Villanova, Valencia, Spain; 3SOLTI Breast Cancer Research Group, Barcelona, Spain; 4Istituto Nazionale dei Tumori, Milan, Italy; 3Brustzentrum, Frauenklinik der Universität München, Germany

BACKGROUND

Chemotherapeutics, particularly microtubule inhibitors, are the backbone of most breast cancer treatment regimens. However, further research into new compounds is needed in order to provide additional options that maximize benefit, minimize toxicity, and most of all, deliver on the promise of personalized medicine.

Eribulin is a nontaxane microtubule dynamics inhibitor with a novel mechanism of action2 that has demonstrated prolonged OS in a Phase III metastatic breast cancer trial. Toxicity was manageable, including a modest incidence of neuropathy, which appears to be lower than that of other antimitotic agents2.

Neoadjuvant trials provide a unique opportunity to rapidly assess the activity of novel compounds and to search for predictive biomarkers of response, without detriment to the patient4.

Gene expression–based assays are becoming the norm in the current standard of care and are expected to supplement, and perhaps in some cases replace, the single-biomarker approaches used in pathology analysis today45.

This study aims to prospectively determine which patients, based on their molecular profiles, can derive the maximum benefit from treatment with erbulin.

OBJECTIVES

Primary

To evaluate the correlation between pre-treatment mRNA expression profiles and clinical benefit from neoadjuvant eribulin, assessed by the rates of pathological complete response in the breast (pCRB).

Secondary

To assess clinical benefit, measured by the rates of pCRB and breast and axilla (pCRAx), as well as overall response.

To determine the correlation between pCRB with breast cancer subtypes as determined by IHC and by FISH.

To determine the biological activity of the treatment with eribulin, assessed by comparing gene expression at different time points and their correlation pCRB rate.

To assess the rate of breast conserving surgery.

To estimate the sensitivity and specificity of the gene expression assay to predict clinical response.

To evaluate the safety and tolerability of the regimen.

To evaluate the rate of fulbitum isotype expression and mutational status in the response to therapy.

To identify other molecular biomarkers of response and/or safety

METHODS

This is a multicenter, single-arm exploratory phase II clinical trial of neoadjuvant, eribulin for the treatment of primary HER2-negative breast cancer.

As the purpose of this study is merely the identification of biomarkers of response, multiple biomarkers will be collected:

- Baseline, 21-day on-treatment, and post-treatment (see Table 1)

- The expression of 542 genes involved in breast cancer will be explored with the NanoString technology using formalin-fixed, paraffin-embedded tissue.

- The expression of single genes and the score of each signature in the pre-treatment and 21-day samples will be correlated with the clinical outcomes.

- Assuming an average pCR in the breast of 15%, a sample size of 200 patients is estimated to provide a 90% probability of detecting a gene signature whose expression is associated with a two-fold increase in odds of achieving a pCR in the breast, assuming 5% of patients would be lost to follow-up and 5% would have insufficient quantity or quality of mRNA.

- The expected rate of pCRB is calculated assuming the following values: 9.0% for luminal A, 6.10% for luminal B, and 20.30% for triple negative.

KEY ELIGIBILITY CRITERIA

- Histologically confirmed invasive breast carcinoma with all of the following characteristics:
  - Primary tumor ≥ cm in largest diameter (cT1-3)
  - Clinically evident axillary lymph nodes (cN0-1)
  - No evidence of distant metastasis (M0)
  - Eligible for definitive primary surgery
  - HER2 negative
  - ECOG performance status of 0 or 1
  - Multifocal tumors are allowed only if:
    - Largest lesion ≥ cm
    - Well documented HER2 status in all tumor foci
  - ER/pHer status of the target lesion by IHC will be used to classify the breast cancer subtype

ACCRAUL

Two hundred patients are planned in 29 sites across in Spain, Germany, Portugal, and France. At least 100 triple-negative breast cancer cases will be included.

Recruitment started in August 2012, with 15 participating patients as of November 2012.

For more information, go to ClinicalTrials.gov (NCT01669252).

ACKNOWLEDGEMENTS

The trial is funded by a grant from Eisai.